Radiopharm Theranostics (RADX) Common Equity (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Common Equity for 2 consecutive years, with $42.9 million as the latest value for Q2 2025.
- On a quarterly basis, Common Equity rose 56.73% to $42.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $42.9 million, a 56.73% increase, with the full-year FY2025 number at $42.9 million, up 56.73% from a year prior.
- Common Equity was $42.9 million for Q2 2025 at Radiopharm Theranostics, up from $27.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $42.9 million in Q2 2025 to a low of $27.4 million in Q2 2024.